Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X:
“ctDNA data for radiotherapy (TMT) in muscle invasive bladder cancer shows 19/59 pts (32%) were ctDNA+ve at baseline (Lower than in NIAGARA 57%). 11/19 had ctDNA clearance with TMT. Those that didn’t clear had higher risk of systemic rather than local relapse, underlining TMTs role in local rather than systemic control. CtDNA helps. Congrats to the team.”
Other articles featuring Tom Powles on OncoDaily.
